B-Domain Deleted Recombinant Coagulation Factor VIII Modified with Monomethoxy Polyethylene Glycol
- 4 April 2000
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 11 (3) , 387-396
- https://doi.org/10.1021/bc990137i
Abstract
Recombinant coagulation factor VIII (r-VIII SQ) was chemically modified with monomethoxy poly(ethylene glycol) (mPEG). Three mPEG derivatives were used for coupling to the r-VIII SQ lysines, a mixed anhydride of monomethoxy poly(ethylene glycol) succinic acid (mPEG-SAH), monomethoxy poly(ethylene glycol) succinimidyl succinate (mPEG-SS), and monomethoxy poly(ethylene glycol) tresylate (mPEG-TRES). A consequence of the modification with all derivatives was a substantial reduction in coagulant activity, even at very low degrees of modification. A method was developed with the purpose of avoiding conjugation at certain important biological sites on the factor VIII and thereby producing conjugates with better retained activity. This was achieved by immobilizing the protein onto a solid matrix during the modification reaction. Characterization of conjugates by SDS−PAGE, western blots, interaction with von Willebrand factor (vWf), and thrombin activation/inactivation analyses was undertaken. The SDS−PAGE and western blots revealed coupling heterogeneity regarding degree of modification. The amount of factor VIII able to bind to vWf decreased with the conjugation. Thrombin activated the modified factor VIII to essentially the same extent as the reference preparation of r-VIII SQ. Inactivation of the modified factor VIII was, however, slower than inactivation of the unmodified protein. Finally, an in vitro study was performed to evaluate the influence of the mPEG modification on the protein stability in extract of porcine tissue. Despite that conjugates with low degrees of modification were included in the study, the coagulant activity was preserved to a significantly higher extent in all incubation mixtures containing conjugates compared to that with unmodified protein.Keywords
This publication has 16 references indexed in Scilit:
- Alkyl 2,2,2-Trifluoroethanesulfonates (Tresylates): Elimination−Addition vs Bimolecular Nucleophilic Substitution in Reactions with Nucleophiles in Aqueous Media1The Journal of Organic Chemistry, 1996
- Inter‐individual variation in half‐life of infused recombinant factor VIII is related to pre‐infusion von Willebrand factor antigen levelsBritish Journal of Haematology, 1995
- Biomedical and biotechnological applications of PEG- and PM-modified proteinsTrends in Biotechnology, 1995
- Analysis of active antibody concentration. Separation of affinity and concentration parametersJournal of Immunological Methods, 1993
- The conjugation of proteins with polyethylene glycol and other polymersAdvanced Drug Delivery Reviews, 1993
- Active Site Protection of Proteolytic Enzymes by Poly(ethylene glycol) Surface ModificationJournal of Bioactive and Compatible Polymers, 1993
- Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activityBiochemistry, 1986
- Inactivation of viruses in labile blood derivatives. I. Disruption of lipid‐enveloped viruses by tri(n‐butyl)phosphate detergent combinationsTransfusion, 1985
- Assay of Factor VIII:C with a Chromogenic SubstrateScandinavian Journal of Haematology, 1984
- Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's diseaseBritish Journal of Haematology, 1982